|
Oct 25
|
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
|
Oct 24
|
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
|
|
Oct 23
|
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
|
|
Oct 21
|
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis
|
|
Oct 21
|
Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
|
|
Oct 3
|
Exploring High Growth Tech Stocks In The US October 2024
|
|
Sep 25
|
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
|
|
Sep 24
|
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
|
|
Aug 28
|
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
|
|
Aug 27
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Aug 15
|
Q2 2024 Arcutis Biotherapeutics Inc Earnings Call
|
|
Aug 15
|
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
|
|
Aug 14
|
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 14
|
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
|
|
Aug 13
|
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long
|
|
Jul 30
|
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
|
|
Jul 29
|
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
|
|
Jul 29
|
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jul 23
|
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
|